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ABSTRACT The receptor for advanced glycation end
products (RAGE), known as a multiligand receptor for
certain stress-associated factors, has been considered to
affect the characteristic differences of various cancer cells.
We analyzed the expression and clinicopathological sig-
nificance of RAGE in esophageal squamous cell
carcinoma. We investigated immunohistochemically the
relationship between RAGE expression and clinicopatho-
logical factors, including prognosis, in surgical specimens
of primary tumors in 216 patients with esophageal squa-
mous cell carcinoma. Prognostic factors were examined by
univariate and multivariate analyses (Cox proportional
hazard regression model). The positive expression rate of
RAGE was 50%. RAGE expression was negatively corre-
lated with depth of invasion and venous invasion.
Moreover, tumors with positive RAGE expression exhib-
ited better prognosis than those with negative RAGE
expression (5-year survival, 52% vs. 32%, respectively).
Multivariate analysis indicated that the positive expression
of RAGE was an independent prognostic factor, along with
tumor depth and nodal metastasis. Our findings suggest that
loss of RAGE expression may play an important role in the
progression of esophageal squamous cell carcinoma.
Evaluation of the expression of RAGE could be useful for
determining the tumor properties, including those associ-
ated with prognosis, in patients with esophageal squamous
cell carcinoma.
The receptor for advanced glycation end products
(RAGE) is a multiligand receptor classified as an immuno-
globulin superfamily cell surface molecule; it acts as a
counterreceptor for high-mobility group box 1 (HMGB1)
proteins, RAGEs, S100/calgranulins, and amyloid-b pep-
tides.1–3 These interactions trigger the activation of key cell
signaling pathways (e.g., p38 and p44/42 MAP kinase, NF-
jB, cdc42/rac, and the generation of reactive oxygen spe-
cies) and result in the production of proinflammatory
cytokines.4–7 RAGE-mediated proinflammatory processes
are now considered to contribute to the progression of many
chronic diseases, such as neuropathy, nephropathy, macro-
vascular disease, amyloidoses, inflammatory conditions
(e.g., rheumatoid arthritis and inflammatory bowel disease),
and sepsis.7–9 In addition to RAGE-mediated proinflamma-
tory events, recent studies have revealed that the interaction
of RAGE and its ligands and the resultant signaling play a
causative role in the characteristic modulation of cancer cell
functions, i.e., increasing tumor invasion and metastasis.10
Furthermore, several clinical studies have demonstrated a
strong association of RAGE expression with the malignant
potential of various cancers such as gastric cancer, colon
cancer, biliary cancer, pancreatic cancer, and prostate can-
cer, although several reports showed a reverse correlation
between RAGE expression and tumor progression.11–19
We previously reported a change in RAGE expression
according to the sequential change of liver tissue.20 The
RAGE expression was higher in the early or prestages of
cancer than in the normal liver or advanced hepatocellular
carcinoma (HCC). An HCC lesion, which is highly asso-
ciated with inflammation caused by either hepatitis viruses
or drugs, develops through a process of multistage carci-
nogenesis, i.e., from inflammatory lesions (e.g., hepatitis,
cirrhosis and precancerous lesion) to dysplastic nodules,
and eventually into HCC.
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Esophagus squamous cell carcinoma (ESCC) is one of
the most aggressive carcinomas of the gastrointestinal tract.
Many studies have identified various biological factors in
the malignant potential of ESCC. ESCC is also thought to
develop through a process of multistage carcinogenesis.
Most ESCC arises from esophageal dysplasia caused by
smoking and drinking. Thus, RAGE expression may be
expected to play an important role in the development of
ESCC, although no data have been reported for this tumor.
In this study, we intended to examine the expression of
RAGE in surgical specimens of ESCC and to provide some
indication of the biological role of RAGE in ESCC.
MATERIALS AND METHODS
Patients and Tumor Specimens
The present study involved 216 consecutive patients
with thoracic ESCC (199 men and 17 women) who
underwent curative surgery at the Kagoshima University
Hospital between January 1987 and December 1998. All of
these patients underwent an esophagectomy with lymph
node dissection. The cases of operation-related death
within 30 days after the esophagectomy were excluded.
The patients ranged in age from 38 to 84 years (mean,
64.1 years). None of these patients underwent endoscopic
mucosal resection, palliative resection, preoperative che-
motherapy, or radiotherapy, and none of them had
synchronous or metachronous multiple cancers in other
organs. Of 216 patients, 117 (54.1%) died of relapse of
ESCC and were categorized as uncensored patients.
Among these patients, 54 experienced lymph node recur-
rences, 50 distant organ recurrence, and 29 local
recurrence. Data from patients who died of disease other
than ESCC or its recurrences were censored.
Specimens of cancer and adjacent noncancerous tissues
were collected from the patients according to the institu-
tional guidelines of our hospital after informed consent had
been obtained. Classifications of the specimens were
determined according to the International Union Against
Cancer tumor-node-metastasis classification system.21 All
of the M1 tumors had distant lymph node metastases. All
patients were followed up after discharge with a chest X-
ray every 1–3 months, computed tomography every 3 to
6 months, and ultrasound every 6 months. Follow-up data
after surgery were available for all patients, with a median
follow-up period of 20 months (range, 2–166 months).
Immunohistochemical Staining and Evaluation
Tumor samples were fixed with 10% formaldehyde in
phosphate-buffered saline (PBS), embedded in paraffin, and
sectioned into 4-lm-thick slices. Immunohistochemical
staining was performed by the conventional immunoperox-
idase technique. After paraffin was removed from the
sections, the endogenous peroxidase was blocked by
immersing the slides in a 3% H2O2-methanol solution for 10
min at room temperature. As preparation for staining with
RAGE antibodies, sections were treated with 1 mM EDTA-
NaOH solution (pH 8.0) for 12 minutes at 100C in a
microwave oven.22 The sections were washed three times
with PBS, each for 5 minutes, and then blocked by treatment
with PBS containing 1.5% normal rabbit serum (Vector
Laboratories, Burlingame, CA, USA) for 30 min at room
temperature. The blocked sections were incubated with pri-
mary antibody RAGE (C-20, Santa Cruz Biotechnology,
Santa Cruz, CA; 1:50), diluted in PBS for 2 h at room tem-
perature, and then incubated with the secondary antibody
conjugated with peroxidase at room temperature. The sec-
tions were washed in PBS for 5 min three times, and the
immune complex was visualized by incubating the sections
with diaminobenzidine tetrahydrochloride. The sections
were rinsed briefly in water, counterstained with Meyer’s
hematoxylin (Sigma Chemical Co., St. Louis, MO), and
mounted. Negative controls were performed by replacing the
primary antibodies with PBS. Evaluation of immunohisto-
chemistry results was independently carried out by two
surgeons (T.T. and S.N.) who had training in digestive
pathology. To evaluate the expressions of RAGE, 10 fields
(within the tumor and at the invasive front) were selected,
and the expression in 1,000 tumor cells (100 per field) was
evaluated with high-power (9200) microscopy. The
immunohistochemical expression of RAGE was defined as
positive if distinct staining of cell membrane or cytoplasm
was observed in at least 10% of tumor cells.
Statistical Analysis
Statistical analysis of group differences was performed
by the v2 test and t-test. The Kaplan–Meier method was
used for survival analysis and differences in survival were
estimated by the log-rank test. Prognostic factors were
examined by univariate and multivariate analyses (Cox
proportional hazard regression model). P \ .05 was con-
sidered to be statistically significant. The P values in this
study were two sided. All statistical analyses were per-
formed by StatView software, version 5.0 (Abacus
Concepts, Berkeley, CA).
RESULTS
Expressions of RAGE in ESCC
Positive and negative expression of RAGE is shown in
Fig. 1. Information for eight patients (3.7% of total) were
discordant among the evaluation of the specimens by the
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two investigators. Such specimens were omitted from this
study. RAGE immunoreactivity was observed in the cell
membrane and cytoplasm of tumor cells, but not in the
nuclei. The RAGE-positive tumor cells frequently formed a
cluster, but the RAGE-negative tumor cells did not
(Fig. 1). Positive RAGE expression was found in 104
(50%) of 208 patients. Nevertheless, in the cases with
tumors with negative RAGE expression, RAGE positive
tumor cells were frequently found in a superficial site
(Fig. 2a) rather than at the invasive front of the tumor
(Fig. 2b). Weak to moderate RAGE immunoreactivity was
observed in basal cells of noncancerous esophageal epi-
thelium (Fig. 3).
Relationship Between the Expression of RAGE
and Clinicopathological Findings
The expression of RAGE was significantly correlated
with depth of tumor invasion and venous invasion. The
tumors with negative RAGE expression invaded deeper
and showed more venous invasion than the tumors with
positive RAGE expression (P = .008 and P = .031,
respectively). Age, sex, tumor location, histology of tumor,
lymph node metastasis, tumor, node, metastasis stage, and
lymphatic invasion were not correlated with the expression
of RAGE (Table 1).
Relationship Between Prognosis and Expression
of RAGE
The 5-year survival rate of patients with tumors
with positive RAGE expression was 52.3%, whereas the
rate for those with negative RAGE expression was
31.8%. There was a statistically significant difference in
overall survival rates between patients with positive and
negative expression of RAGE (Fig. 4). In disease-free
survival, there was also a significant difference between
RAGE-positive and -negative groups (P = .0020, 3-year
disease-free survival rates were 54.8 and 33.7%,
respectively).
FIG. 1 Receptor for advanced glycation end products (RAGE)
expression in esophageal squamous cell carcinoma (ESCC). a, b
Positive RAGE expression (original magnification, 9200). Almost
tumor cells show moderate to strong immunoreactivity (arrows). c, d
Negative RAGE expression (original magnification, 9200). Almost
tumor cells show no or weak immunoreactivity
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Uni- and Multivariate Analysis of Prognostic Factors
in ESCC
Univariate analysis showed that the following factors
were significantly related to postoperative survival: his-
tology, tumor depth, lymph node metastasis, stage,
lymphatic invasion, venous invasion, and RAGE expres-
sion (P \ .05) (Table 2). Multivariate regression analysis
indicated that depth of invasion, lymph node metastasis,
and RAGE expression were independent prognostic factors
(Table 3).
DISCUSSION
In the present study, we immunohistochemically inves-
tigated the relationship between RAGE expression and
clinicopathological factors, including prognosis in ESCC.
Our results show that negative RAGE expression correlates
with deeper tumor invasion and venous invasion. Our data
are consistent with observations in non–small lung carci-
noma cells, in which downregulation of RAGE signaling
was associated with tumor stage and with previous work
showing that RAGE-induced neuronal differentiation was
associated with proliferation arrest.15,23 Moreover, one
study reported that RAGE expression in rhabdomyosar-
coma reduced proliferation, migration, invasiveness and
tumor growth, and functional inactivation of RAGE in L6
myoblasts resulted in increased proliferation and tumor
formation in vivo.19,24 These data are also consistent with
our results and suggest that a decrease in RAGE signaling
is associated with tumor progression. However, our
observations are at variance with the data obtained with
glioma, gastric cancer, colon cancer, biliary cancer, and
human pancreatic carcinoma cells, in which a positive
correlation was found between RAGE expression, tumor
progression, and metastasis.10–15 One study reported that
RAGE expression positively correlates with the degree of
atypia in colorectal adenomas because 90% (18 of 20) of
adenomas with severe atypia express RAGE.25 However,
in another study, investigators reported that RAGE posi-
tivity in cases with Dukes’ B, C, and D stage colorectal
cancer was 19, 81, and 100%, respectively.13 There was a
conflict between their results in colorectal adenoma and
those in colorectal cancer according to the adenoma-ade-
nocarcinoma sequence theory. Some of these conflicts may
have a basis. RAGE interacts with several extracellular
ligands that can be produced by the cell or by neighboring/
circulating cells. Therefore, the tumor cells influence each
other. Moreover, most RAGE ligands also fulfill intracel-
lular functions independent of RAGE.
Another aspect of the biology of RAGE was suggested
by the features of retinoic acid–induced neuroblastoma
FIG. 2 Positive expression of the receptor for advanced glycation end products (RAGE) was found in the tumor cells of the superficial site (a,
arrow) (original magnification, 9200), but not in the tumor cells of the invasive front in the same case (b, arrow) (original magnification, 9200)
FIG. 3 Expression of receptor for advanced glycation end products
(RAGE) was observed in basal cells of normal esophageal epithelium
(arrow) (original magnification, 9200)
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differentiation in which RAGE expression played a more
important role in cellular survival than neurite outgrowth.26
In this model, inhibition of RAGE function partially
blocked the increase in levels of the antiapoptotic protein
Bcl-2 during the process of neuronal differentiation, indi-
cating that RAGE and its signaling also might contribute to
the survival of certain cancer cell types undergoing ‘‘dif-
ferentiation.’’ We previously reported that increased RAGE
expression was highly associated with the status of ‘‘dif-
ferentiation’’ in HCC, which played an important role in
acquisition of the hypoxia-resistant phenotype of tumor
cells.20 Some recent studies revealed the differentiation-
promoting activity of HMGB1/RAGE in neurons and L6
myoblasts.5,27 These studies’ findings are consistent with
our results in HCC and emphasize that RAGE may play an
important role in cellular differentiation. According to our
current detailed observations, RAGE was highly expressed
in noncancerous basal cells of esophageal epithelium.
Basal cells of esophageal epithelium are actively differ-
entiating into squamous epithelial cells. This observation
supports the hypothesis that RAGE plays some key roles in
cellular differentiation. Moreover, one study reported a
positive correlation between RAGE immunoreactivity and
histologic differentiation in oral squamous cell carci-
noma.18 However, in the present study, RAGE expression
in ESCC showed no marked correlation with ‘‘pathologi-
cal’’ differentiation. Our previous report revealed that there
was no marked correlation between the status of patho-
logical differentiation and the expression of E-cadherin,
which is one of the major intercellular adhesion mole-
cules.28,29 The phenotype of E-cadherin expression might
be recognized as one of the indicators of cellular differ-
entiation in the epithelial cells. Therefore, pathological
differentiation may not always reflect the cellular differ-
entiation in the ESCC.
Our results show that negative RAGE expression cor-
relates not only with deeper tumor invasion but also with
the venous invasion. Because the esophageal wall and
veins are common smooth muscle structures, the loss of
TABLE 1 Relationship between receptor for advanced glycation end
















Male 192 99 (95.2) 93 (89.4) .1185
Female 16 5 (4.8) 11 (10.6)
Tumor location
Upper 28 14 (13.5) 14 (13.5) .8973
Middle 115 59 (56.7) 56 (53.8)
Lower 65 31 (29.8) 34 (32.7)
Histology
Well 73 32 (30.8) 41 (39.4) .4089
Moderate 97 51 (49.0) 46 (16.4)
Poor 38 21 (20.2) 17 (44.2)
pT
pT1 47 31 (29.8) 16 (15.4) .0075
pT2 29 19 (18.3) 10 (9.6)
pT3 87 36 (34.6) 51 (49.0)
pT4 45 18 (17.3) 27 (26.0)
pN
pN0 77 40 (38.5) 37 (35.6) .6666
pN1 131 64 (61.5) 67 (64.4)
pM
pM0 147 75 (72.1) 72 (69.2) .6477
pM1 61 29 (27.9) 32 (30.8)
Stage
I 30 20 (19.2) 10 (9.6) .2266
IIA 39 18 (17.3) 20 (19.2)
IIB 24 14 (13.5) 10 (9.6)
III 55 23 (22.1) 32 (30.8)
IV 61 29 (27.9) 32 (30.8)
Lymphatic invasion
Negative 72 38 (36.5) 34 (32.7) .5599
Positive 136 66 (63.5) 70 (67.3)
Venous invasion
Negative 131 73 (70.2) 58 (55.8) .0312


















FIG. 4 Postoperative overall survival curves according to the
expression of receptor for advanced glycation end products (RAGE).
There was a statistically significant difference in survival between the
patients with positive and negative expressions of RAGE (P = .0003)
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RAGE expression may promote smooth muscle invasion
by ESCC. We thought that some change in the microenv-
iroment surrounding tumor cells may occur when the tumor
cells invade smooth muscle tissue. Changes in the micro-
enviroment may change the RAGE signaling and influence
tumor invasion. As these results show, it seems that neg-
ative RAGE expression became an independent prognostic
factor similar to depth of tumor invasion and lymph node
metastasis. Various proteins have been considered as
prognostic factors of ESCC. RAGE is an interesting mol-
ecule not only as a prognostic factor but also in regard to
carcinogenesis or oncogenesis.
In conclusion, RAGE expression was negatively asso-
ciated with depth of invasion, venous invasion, and
prognosis. Our findings have provided the first evidence of
the clinical relevance and function of RAGE in ESCC.
Although other mechanisms may also be important, our
data indicate that RAGE and its functions may be possible
candidates for therapeutic targets in the treatment of ESCC.
In addition, because RAGE expression was an independent
prognostic factor, evaluation of RAGE expression may be
useful for predicting malignant properties of ESCC.
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